RhoA as a mediator of clinically relevant androgen action in prostate cancer cells

Medicine & Life Sciences

• Serum Response Factor 100%
• Androgens 62%
• Prostatic Neoplasms 54%
• Leukemia, Megakaryoblastic, Acute 35%
• Androgen Receptors 18%
• Genes 18%
• rho-Associated Kinases 14%
• Castration 12%
• Prostate 9%
• Monomeric GTP-Binding Proteins 6%
• GTP Phosphohydrolases 6%
• Protein Kinase Inhibitors 6%
• Polymerization 5%
• Prostatectomy 5%
• Disease-Free Survival 5%
• Heterografts 5%
• Actins 4%
• Cell Movement 4%
• Disease Progression 4%
• Binding Sites 4%
• Cell Line 3%
• Recurrence 3%
• Neoplasms 1%
• Therapeutics 0%